Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
GastroEsophageal Cancer

New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer

Ulas D. Bayraktar, MD
2024-11-11
Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Ulas D. Bayraktar, MD
2024-09-30
Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Ulas D. Bayraktar, MD
2024-08-27
Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Ulas D. Bayraktar, MD
2024-06-24
Mesothelioma

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

Ulas D. Bayraktar, MD
2024-06-22
Uterine Cancer

New Protocol: Durvalumab with CARBOplatin and PACLitaxel for Endomterial Cancer

Ulas D. Bayraktar, MD
2024-06-21
Non-Small Cell Lung Cancer

New Drug: Repotrectinib for ROS1-fusion positive NSCLC

Ulas D. Bayraktar, MD
2024-06-21
Small Cell Lung Cancer

New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

Ulas D. Bayraktar, MD
2024-06-21
Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Ulas D. Bayraktar, MD
2024-01-13
GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

Ulas D. Bayraktar, MD
2023-11-20

Posts pagination

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj